Abgrall S, Rachas A, Tourret J, Isnard-Bagnis C, Billaud E, Tattevin P, et al. A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomized trial. Clin Infect Dis. 1 août 2015;61(3):375‑84. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25904366
Antiretroviral Therapy Cohort Collaboration (ART-CC). Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. Antivir Ther. 2015;20(1):21‑8. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24675571
Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende M-A, Ingle S, May M, Chene G, Zangerle R, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 28 janv 2015;29(3):373‑83. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25686685
Bruyand M, Le Marec F, Lavole A, Leffondre K, Spano JP, Le Moing V, et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS. 1 juin 2015;29(9):1105‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26125142
Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 1 janv 2015;35(1):65‑70. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25040895
Champredon D, Bellan SE, Delva W, Hunt S, Shi C-F, Smieja M, et al. The effect of sexually transmitted co-infections on HIV viral load amongst individuals on antiretroviral therapy: a systematic review and meta-analysis. BMC Infect Dis. 30 juin 2015;15(1):249. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26123030
de Monteynard L-A, Dray-Spira R, de Truchis P, Grabar S, Launay O, Meynard J-L, et al. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France. PLoS One. 3 mars 2015;10(3):e0118492. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25734445
Delaugerre C, Ghosn J, Lacombe J-M, Pialoux G, Cuzin L, Launay O, et al. Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access. Clin Infect Dis. 1 févr 2015;60(3):463‑72. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25344539
Denis B, Guiguet M, de Castro N, Mechaï F, Revest M, Melica G, et al. Relevance of EORTC Criteria for the Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival Trends Over a 20-Year Period in France. Clin Infect Dis. 15 oct 2015;61(8):1273‑80. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26123932
Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 15 avr 2015;60(8):1269‑77. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25601456
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS. 14 janv 2015;29(2):221‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25426809
HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, et al. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clin Infect Dis. 15 avr 2015;60(8):1262‑8. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25567330
Hleyhel M, Belot A, Bouvier A-M, Tattevin P, Pacanowski J, Genet P, et al. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J cancer. 15 nov 2015;137(10):2443‑53. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25976897
Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, et al. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? AIDS. 1 nov 2015;29(17):2323‑33. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26544704
Lang S, Lacombe J-M, Mary-Krause M, Partisani M, Bidegain F, Cotte L, et al. Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort. PLoS One. 22 juill 2015;10(7):e0133358. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26200661
Late presenters working group in COHERE in EuroCoord, Mocroft A, Lundgren J, Antinori A, Monforte A d’Arminio, Brännström J, et al. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 2015;20(47). Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26624933
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. lancet HIV. 1 août 2015;2(8):e335-43. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26423376
Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, et al. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS. 14 janv 2015;29(2):193‑200. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25426810
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, et al. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr. 1 juill 2015;69(3):348‑54. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25848927
Migrants Working Group on behalf of COHERE in EuroCoord. Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. lancet HIV. 1 déc 2015;2(12):e540-9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26614968
Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, et al. Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice. PLoS One. 1 déc 2015;10(12):e0144746. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26714012
Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: prevalence and surgical treatment options. J Visc Surg. 1 févr 2015;152(1):33‑7. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25662869
Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med. 1 avr 2015;16(4):230‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25522874
Vandenhende M-A, Roussillon C, Henard S, Morlat P, Oksenhendler E, Aumaitre H, et al. Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. PLoS One. 17 juin 2015;10(6):e0129550. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26083524
